MedTrace Logo

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

NCT00115635 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-10-02

No results posted yet for this study

Summary

The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II trial.

Conditions

Interventions

DRUG

docetaxel

DRUG

gemcitabine

Sponsors & Collaborators

Principal Investigators

  • Lisa Sengelov, MD · Dept. of Oncology, Herlev Hospital, 2730 Herlev, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115635 on ClinicalTrials.gov